RESIDUAL, PROGRESSIVE OR RECURRENT GRADE II OR III MENINGIOMA

Clinical trials for RESIDUAL, PROGRESSIVE OR RECURRENT GRADE II OR III MENINGIOMA explained in plain language.

Never miss a new study

Get alerted when new RESIDUAL, PROGRESSIVE OR RECURRENT GRADE II OR III MENINGIOMA trials appear

Sign up with your email to follow new studies for RESIDUAL, PROGRESSIVE OR RECURRENT GRADE II OR III MENINGIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Sniffing a potential new weapon against tough brain tumors

Disease control Recruiting now

This study is testing an inhaled therapy called NEO100 for people with aggressive, recurrent meningioma brain tumors that have returned or grown after surgery and radiation. The therapy is a plant-based compound sniffed through the nose four times a day, aiming to deliver treatme…

Matched conditions: RESIDUAL, PROGRESSIVE OR RECURRENT GRADE II OR III MENINGIOMA

Phase: PHASE2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

RESIDUAL, PROGRESSIVE OR RECURRENT GRADE II OR III MENINGIOMA

Get alerted when new RESIDUAL, PROGRESSIVE OR RECURRENT GRADE II OR III MENINGIOMA trials appear

Sniffing a potential new weapon against tough brain tumors